Compounds > 1-phenyl-2-decanoylamino-3-morpholino-1-propanol

1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Experimental Neoplasms

1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with Experimental Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, CL; Chen, TY; Chen, YP; Cheng, YL; Hsieh, CY; Huang, WC; Lin, CF; Lin, CM; Lin, YS; Lu, PJ; Tsai, CC; Tsao, CW; Tseng, PC; Wang, CY; Wang, SH1
Inokuchi, J; Inoue, M; Kyogashima, M; Seto, A1

Other Studies

2 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Experimental Neoplasms

ArticleYear
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:10

    Topics: 1-Deoxynojirimycin; Animals; Apoptosis; Cell Line, Tumor; Ceramides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, abl; Glucosyltransferases; Glycogen Synthase Kinase 3; Humans; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Mice; Mice, SCID; Morpholines; Mutation; Neoplasms, Experimental; Pyrimidines; Transplantation, Heterologous

2011
Glucosylceramide synthetase inhibitor, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol exhibits a novel decarcinogenic activity against Shope carcinoma cells.
    Cancer letters, 1996, Mar-19, Volume: 101, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Division; Glucosyltransferases; Mice; Mice, Nude; Morpholines; Neoplasms, Experimental; Rabbits; Tumor Cells, Cultured; Tumor Stem Cell Assay

1996